Maxim Group analyst Jason McCarthy reiterated his Buy rating and $14 price target on Inovio Pharmaceuticals (NASDAQ: INO) as MERS ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Intrexon (XON), Inovio Pharma (INO) Moving Back to Highs on Zika OutbreakJanuary 28, 2016 11:08 AM Inovio Pharma (INO), GeneOne Initiate Patient Recruitment for MERS Vaccine TrialJanuary 28, 2016 8:34 AM Intrexon (XON), Inovio Pharma (INO) on Watch as Zika Virus 'Spreading Explosively'January 28, 2016 8:19 AM Inovio Pharmaceuticals and GeneOne Life Science Initiate Patient Recruitment for MERS Vaccine TrialJanuary 28, 2016 7:00 AM Inovio Pharma (INO) Sees Upside Amid Ongoing Zika Virus Headlines, WorriesJanuary 27, 2016 9:46 AM